New Oral AntiCoagulants Use in REnal Disease and AF (NOACURE-AF) Where do we stand?: An expert consensus view using the Delphi method [Turk Kardiyol Dern Ars]
New Oral AntiCoagulants Use in REnal Disease and AF (NOACURE-AF) Where do we stand?: An expert consensus view using the Delphi method
Mustafa Arıcı1, Tevfik Ecder2, İzzet Erdinler3, Ercan Ok4, Özlem Arıcan Özlük5, Uğur Önsel Türk6, Emin Alioğlu61Department of Nephrology, Hacettepe University School of Medicine, Ankara, Turkey 2Department of Nephrology, Demiroğlu Bilim University School of Medicine, İstanbul, Turkey 3Department of Cardiology, Memorial Ataşehir Hospital, İstanbul, Turkey 4Department of Nephrology, Ege University School of Medicine, İzmir, Turkey 5Department of Cardiology, Yüksek İhtisas Training and Research Hospital, Bursa, Turkey 6Department of Cardiology, İzmir Economy University School of Medicine, İzmir, Turkey Keywords: Atrial fibrillation, non-vitamin K antagonist anticoagulants (NOACs), end-stage renal disease
Corresponding Author: Emin Alioğlu, Türkiye Manuscript Language: English